Search

Your search keyword '"Soto Parra H"' showing total 126 results
Start Over Author "Soto Parra H"
126 results on '"Soto Parra H"'

1. EP02.04-001 Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-Positive NSCLC: ALNEO Phase II Trial (GOIRC-01-2020)

Author

Leonetti, A., primary, Minari, R., additional, Boni, L., additional, Gnetti, L., additional, Bordi, P., additional, Verzè, M., additional, Ampollini, L., additional, Gelsomino, F., additional, Toschi, L., additional, Cecere, F., additional, Pilotto, S., additional, Metro, G., additional, Passiglia, F., additional, Cortinovis, D., additional, Guaitoli, G., additional, Pasello, G., additional, Delmonte, A., additional, Mazzoni, F., additional, Bria, E., additional, Galetta, D., additional, Genova, C., additional, Rocco, D., additional, Soto Parra, H., additional, Bearz, A., additional, Migliorino, M.R., additional, Camerini, A., additional, Tognetto, M., additional, and Tiseo, M., additional

Published
2022
Full Text
View/download PDF

2. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

Author

Floriani, I., Rulli, E., Cropalato Di Tullio, M., Poli, D., Galli, F., Biagioli, E., De Simone, I., Mangano, S., Tonato, M., Zucca, E., Valsecchi, M.G., Bajetta, E., Di Bartolomeo, M., Labianca, R., Amadori, D., Falcone, A., Di Costanzo, F., Daniele, B., Pinto, C., Comella, G., Nitti, D., Mini, E., De Placido, S., Marchet, A., Catena, L., Schiavo, M., Pinotti, G., Proserpio, I., Rosati, G., Bordonaro, R., Cordio, S., Burrafato, G., Bochicchio, A.M., Aieta, M., Fazio, N., Spada, F., Amoroso, V., Marini, G., Soto Parra, H., Novello, G., Massidda, B., Ionta, M.T., Comandè, M., Venezia, R., Bertolini, A., Menatti, E., Zanlorenzi, L., Colombo, A., Iop, A., Bonura, S., Mazza, E., Viganò, M., Ardizzoia, A., Dell'Oro, S., Lo Re, G., Santeufemia, D., Buonadonna, A., Luisi, D., Ucci, G., Di Lucca, G., Bonetti, A., Bergamo, F., Alù, M., Vastola, F., Marchetti, P., Corsi, D.C., Massa, E., Di Pinto, G., Duro, M., Oliani, C., Franchini, M., Inzoli, A., Gebbia, N., Repetto, L., Rota, S., Frontini, L., Mosconi, S., Quadri, A., De Grossi, S., Bidoli, P., Cazzaniga, M.E., Villa, F., Foa, P., Ferrari, D., Aitini, E., Rabbi, C., Barni, S., Petrelli, F., Giordano, M., Luchena, G., Pirovano, M., Nasisi, A., Catalano, V., Giordani, P., Zaniboni, A., Leone, F., Ferrario, S., Beretta, G.D., Menichetti, E.T., Conte, D., Mari, D., Giannicola, R., Pierantoni, C., Luporini, A.G., Ravaioli, A., Tassinari, D., Nicolini, M., Frassineti, G.L., Turci, D., Zumaglini, F., Tamberi, S., Piancastelli, A., Cruciani, G., Landi, L., Minuti, G., Cantore, M., Orlandi, M., Mambrini, A., Ciarlo, A., Cavaciocchi, D., Del Monte, F., Ricci, S., Brunetti, M.I., Lencioni, M., Sisani, M., Sozzi, P., Granetto, C., Chiara, S., Galetto, A.S., Ribecco, A.S., DeCensi, A., Ciuffreda, L., Baldini, E.E., Camisa, R., Todeschini, R., Santoro, A., Rimassa, L., Carnaghi, C., Pressiani, T., Boni, C., Rondini, E., Gnoni, R., Gasperoni, S., Cavanna, L., Palladino, M.A., Mattioli, R., Laici, G., Pucci, F., Alessio, M.D., Bernardini, I., Tomasello, G., Baldino, G., Rossetti, R., Giaquinta, S., Di Fabio, F., Rijas Llimpe, F.L., Brandes, A.A., Marzola, M., Montesarchio, V., Rea, A., Genua, G., Casaretti, R., Silvestro, L., Montano, M., Sarobba, M.G., Sanna, G., Filippelli, G., Dima, G., Greco, E., Roselli, M., Natale, D., Condemi, G., Fumi, G., Tafuto, S., Masullo, P., Tiberio, G., de Manzoni, G., Fiorentini, G., Mazzanti, R., Carlomagno, C., De Stefano, A., Cartenì, G., and Otero, M.

Published
2014
Full Text
View/download PDF

3. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

Author

Shaw, A. T., Bauer, T. M., De Marinis, F., Felip, E., Goto, Y., Liu, G., Mazieres, J., Kim, D. -W., Mok, T., Polli, A., Thurm, H., Calella, A. M., Peltz, G., Solomon, B. J., and Soto Parra, H.

Subjects
Male, Alectinib, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung/drug therapy, medicine.medical_treatment, 030204 cardiovascular system & hematology, Macrocyclic, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, hemic and lymphatic diseases, Anaplastic lymphoma kinase, Anaplastic Lymphoma Kinase, 030212 general & internal medicine, Non-Small-Cell Lung, Manchester Cancer Research Centre, General Medicine, Middle Aged, Crizotinib/adverse effects, Intention to Treat Analysis, Female, Hyperlipidemias/chemically induced, medicine.drug, Adult, Lactams, Macrocyclic/adverse effects, Lactams, Lactams, Macrocyclic, Anaplastic Lymphoma Kinase/antagonists & inhibitors, Antineoplastic Agents, Hyperlipidemias, 03 medical and health sciences, Crizotinib, ROS1, medicine, Humans, Lung Neoplasms/drug therapy, Lung cancer, Aged, Chemotherapy, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Carcinoma, Cancer, Antineoplastic Agents/adverse effects, medicine.disease, Survival Analysis, Lorlatinib, Mutation, Cancer research, business
Abstract

BACKGROUND: Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with ALK-positive non-small-cell lung cancer (NSCLC). The efficacy of lorlatinib, as compared with that of crizotinib, as first-line treatment for advanced ALK-positive NSCLC is unclear. METHODS: We conducted a global, randomized, phase 3 trial comparing lorlatinib with crizotinib in 296 patients with advanced ALK-positive NSCLC who had received no previous systemic treatment for metastatic disease. The primary end point was progression-free survival as assessed by blinded independent central review. Secondary end points included independently assessed objective response and intracranial response. An interim analysis of efficacy was planned after approximately 133 of 177 (75%) expected events of disease progression or death had occurred. RESULTS: The percentage of patients who were alive without disease progression at 12 months was 78% (95% confidence interval [CI], 70 to 84) in the lorlatinib group and 39% (95% CI, 30 to 48) in the crizotinib group (hazard ratio for disease progression or death, 0.28; 95% CI, 0.19 to 0.41; PCONCLUSIONS: In an interim analysis of results among patients with previously untreated advanced ALK-positive NSCLC, those who received lorlatinib had significantly longer progression-free survival and a higher frequency of intracranial response than those who received crizotinib. The incidence of grade 3 or 4 adverse events was higher with lorlatinib than with crizotinib because of the frequent occurrence of altered lipid levels. (Funded by Pfizer; CROWN ClinicalTrials.gov number, NCT03052608.).

Published
2020

4. Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study

Author

Lonardi, S., Nasti, G., Fagnani, D., Gemma, D., Ciuffreda, L., Granetto, C., Lucchesi, S., Ballestrero, A., Biglietto, M., Proserpio, I., Bergamo, F., Proietti, E., Tonini, G., and Soto Parra, H

Subjects
Adult, Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Genotype, Bevacizumab, Colorectal cancer, First line, Angiogenesis Inhibitors, Metastatic colorectal cancer, bevacizumab, clinical practice, progression-free survival, therapy interruption, Disease-Free Survival, Proto-Oncogene Proteins p21(ras), 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Humans, Medicine, Progression-free survival, Neoplasm Metastasis, Aged, business.industry, General Medicine, Middle Aged, medicine.disease, Discontinuation, 030104 developmental biology, Italy, 030220 oncology & carcinogenesis, Mutation, Mutation (genetic algorithm), Female, Observational study, Colorectal Neoplasms, business, medicine.drug
Abstract

Aims: BEAWARE investigated the pattern of first-line bevacizumab early interruption in the Italian real-world setting of metastatic colorectal cancer. Methods: A total of 386 patients were followed for 15 months after first-line chemotherapy + bevacizumab start. The rate of bevacizumab interruption for progression or adverse drug reactions (ADRs) constituted the primary endpoint. Results: A total of 78.2% of patients interrupted bevacizumab: 56.6% for progression, 7.3% for ADRs, and 36.1% for other reasons. Median treatment duration was 6.7, 2.5, and 4.6 months, respectively. Median progression-free survival was 10.3 months; however, 35.8% of patients were not progressed and were thus censored at the data cutoff of 15 months, while 21.8% were still receiving bevacizumab. Patients discontinuing for progression/ADRs more frequently had metastases in >1 site ( p = .0001), and a shorter median progression-free survival (6.9 vs 13.9 months, p < .0001). Conclusions: In Italy, first-line bevacizumab is interrupted mainly for progression, only 7.3% due to adverse events, and about one third of cases for other reasons. In clinical practice, the attitude to treat until progression as per guidelines might be implemented. ClinicalTrials.gov Identifier: NCT01609075

Published
2019

5. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

Author

Bajetta, E., Floriani, I., Di Bartolomeo, M., Labianca, R., Falcone, A., Di Costanzo, F., Comella, G., Amadori, D., Pinto, C., Carlomagno, C., Nitti, D., Daniele, B., Mini, E., Poli, D., Santoro, A., Mosconi, S., Casaretti, R., Boni, C., Pinotti, G., Bidoli, P., Landi, L., Rosati, G., Ravaioli, A., Cantore, M., Di Fabio, F., Aitini, E., Marchet, A., Floriani, I., Rulli, E., Cropalato Di Tullio, M., Poli, D., Galli, F., Biagioli, E., De Simone, I., Poli, D., Mangano, S., Tonato, M., Zucca, E., Valsecchi, MG., Floriani, I., Bajetta, E., Di Bartolomeo, M., Labianca, R., Amadori, D., Falcone, A., Di Costanzo, F., Daniele, B., Pinto, C., Comella, G., Nitti, D., Mini, E., De Placido, S., Marchet, A., Bajetta, E., Di Bartolomeo, M., Catena, L., Schiavo, M., Pinotti, G., Proserpio, I., Rosati, G., Bordonaro, R., Cordio, S., Burrafato, G., Bochicchio, A.M., Aieta, M., Fazio, N., Spada, F., Amoroso, V., Marini, G., Soto Parra, H., Novello, G., Massidda, B., Ionta, M.T., Comandè, M., Venezia, R., Bertolini, A., Menatti, E., Zanlorenzi, L., Colombo, A., Iop, A., Bonura, S., Mazza, E., Viganò, M., Ardizzoia, A., DellʼOro, S., Lo Re, G., Santeufemia, D., Buonadonna, A., Luisi, D., Ucci, G., Di Lucca, G., Bonetti, A., Bergamo, F., Alù, M., Vastola, F., Marchetti, P., Corsi, D.C., Massa, E., Di Pinto, G., Duro, M., Oliani, C., Franchini, M., Inzoli, A., Gebbia, N., Repetto, L., Rota, S., Frontini, L., Labianca, R., Mosconi, S., Quadri, A., De Grossi, S., Bidoli, P., Cazzaniga, M.E., Villa, F., Foa, P., Ferrari, D., Aitini, E., Rabbi, C., Barni, S., Petrelli, F., Giordano, M., Luchena, G., Pirovano, M., Nasisi, A., Catalano, V., Giordani, P., Zaniboni, A., Leone, F., Ferrario, S., Beretta, G.D., Menichetti, E.T., Conte, D., Mari, D., Giannicola, R., Pierantoni, C., Luporini, A.G., Ravaioli, A., Tassinari, D., Nicolini, M., Amadori, D., Frassineti, G.L., Turci, D., Zumaglini, F., Tamberi, S., Piancastelli, A., Cruciani, G., Falcone, A., Landi, L., Minuti, G., Cantore, M., Orlandi, M., Mambrini, A., Ciarlo, A., Cavaciocchi, D., Del Monte, F., Ricci, S., Brunetti, M.I., Lencioni, M., Sisani, M., Sozzi, P., Granetto, C., Chiara, S., Galetto, A.S., Ribecco, A.S., DeCensi, A., Ciuffreda, L., Baldini, E.E., Camisa, R., Todeschini, R., Santoro, A., Rimassa, L., Carnaghi, C., Pressiani, T., Boni, C., Rondini, E., Gnoni, R., Di Costanzo, F., Gasperoni, S., Cavanna, L., Palladino, M.A., Mattioli, R., Laici, G., Pucci, F., Alessio, M.D., Bernardini, I., Tomasello, G., Baldino, G., Rossetti, R., Giaquinta, S., Pinto, C., Di Fabio, F., Rijas Llimpe, F.L., Brandes, A.A., Marzola, M., Montesarchio, V., Rea, A., Daniele, B., Genua, G., Casaretti, R., Silvestro, L., Montano, M., Sarobba, M.G., Sanna, G., Filippelli, G., Dima, G., Greco, E., Roselli, M., Natale, D., Condemi, G., Fumi, G., Tafuto, S., Masullo, P., Nitti, D., Marchet, A., Tiberio, G., de Manzoni, G., Fiorentini, G., Mazzanti, R., Carlomagno, C., De Stefano, A., Cartenì, G., and Otero, M.

Published
2014
Full Text
View/download PDF

6. Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial

Author

Di Bartolomeo, M., Morano, F., Raimondi, A., Miceli, R., Corallo, S., Tamborini, E., Perrone, F., Antista, M., Niger, M., Pellegrinelli, A., Randon, G., Pagani, F., Martinetti, A., Fuca, G., Pietrantonio, F., and Soto Parra, H.

Subjects
0301 basic medicine, Oncology, PD-L1, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Docetaxel, B7-H1 Antigen, 03 medical and health sciences, 0302 clinical medicine, Stomach Neoplasms, Internal medicine, Post-hoc analysis, Gastrointestinal Cancer, Antineoplastic Combined Chemotherapy Protocols, medicine, Tumor Microenvironment, Humans, Chemotherapy, Adjuvant, business.industry, Microsatellite instability, Cancer, medicine.disease, Prognosis, Adjuvant chemotherapy, Regimen, 030104 developmental biology, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, FOLFIRI, Biomarker (medicine), Fluorouracil, Cisplatin, business, Gastric cancer, Biomarkers, medicine.drug
Abstract

BACKGROUND: Patients with high microsatellite instability (MSI) gastric cancer (GC) show improved survival and no benefit or harm from adjuvant and/or perioperative chemotherapy. The role of immune microenvironment in GC is largely unknown. MATERIALS AND METHODS: In the present study, 256 tumor tissue blocks were centrally collected from patients enrolled in ITACA‐S, a randomized adjuvant trial of 5‐FU/LV versus sequential FOLFIRI and cisplatin‐docetaxel. MSI status was assessed by multiplex PCR, inflammatory reaction by H&E morphological assessment, and programmed death‐ligand 1 (PD‐L1) expression by immunohistochemistry. RESULTS: Overall, 9% patients had MSI‐high tumors, 23% had high inflammatory reaction, 11% had tumor PD‐L1 ≥ 1%, and 11% had stromal PD‐L1 ≥ 1%. A significant association with disease‐free survival (DFS) and overall survival (OS) was found for MSI‐high (hazard ratio [HR], 0.43; p = .02; HR, 0.40; p = .02) and high inflammatory reaction (HR, 0.55; p = .010; HR, 0.53; p = .008) but not for PD‐L1. At multivariable analysis, only MSI showed an independent association with both DFS (p = .02) and OS (p = .01), whereas inflammatory reaction showed an independent association only with OS (p = .04). Patients with tumor PD‐L1 ≥ 1% had a significantly longer DFS in sequential chemotherapy than in than 5‐FU/LV arm (interaction p = .04) and a trend for OS (interaction p = .12). CONCLUSION: Our data suggest that MSI status could be a useful prognostic biomarker in patients with radically resected stage II–III GC and should be used as stratification factor in future trials. Tumor PD‐L1 ≥ 1% should be further investigated as a potential predictor of benefit from intensive chemotherapy. IMPLICATIONS FOR PRACTICE: In this post hoc analysis of patients with radically resected gastric cancer randomized to an intensive sequential chemotherapy regimen versus 5‐FU/LV monotherapy as adjuvant treatment in the ITACA‐S trial, MSI‐high status was independently associated with better disease‐free survival and overall survival (OS) and inflammatory reaction was independently associated with better OS. Moreover, tumor PD‐L1 expression ≥1% was associated with greater benefit from intensive sequential chemotherapy compared with 5‐fluorouracil plus leucovorin (5‐FU/LV), whereas PD‐L1 expression

Published
2020

7. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Author

Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodriguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., Finley, G., Kelsch, C., Lee, A., Coleman, S., Deng, Y., Shen, Y., Kowanetz, M., Lopez-Chave, A., Sandler, A., Reck, M., Soto Parra, H, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Pulmonologie, and MUMC+: MA Med Staf Spec Longziekten (9)

Subjects
0301 basic medicine, Oncology, Male, Vascular Endothelial Growth Factor A, Lung Neoplasms, MULTICENTER, THERAPY, B7-H1 Antigen, Carboplatin, chemistry.chemical_compound, 0302 clinical medicine, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Medicine, Anaplastic Lymphoma Kinase, Neoplasm Metastasis, Non-Small-Cell Lung, DOCETAXEL, education.field_of_study, Aged, Antibodies, Monoclonal, Bevacizumab, Carcinoma, Non-Small-Cell Lung, Female, Genes, erbB-1, Humans, Middle Aged, Mutation, Paclitaxel, Receptor Protein-Tyrosine Kinases, Survival Analysis, Immunotherapy, Hazard ratio, PHASE-III TRIAL, General Medicine, CHEMOTHERAPY, OPEN-LABEL, CANCER, Docetaxel, 030220 oncology & carcinogenesis, medicine.drug, medicine.medical_specialty, Population, BEVACIZUMAB, Antibodies, 03 medical and health sciences, Atezolizumab, Internal medicine, Lung cancer, education, Survival analysis, erbB-1, business.industry, Carcinoma, medicine.disease, 030104 developmental biology, chemistry, Genes, ANTIBODY, CELLS, business
Abstract

Background The cancer-cell–killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor–mediated immunosuppression with bevacizumab. This open-label, phase 3 study evaluated atezolizumab plus bevacizumab plus chemotherapy in patients with metastatic nonsquamous non–small-cell lung cancer (NSCLC) who had not previously received chemotherapy. Methods We randomly assigned patients to receive atezolizumab plus carboplatin plus paclitaxel (ACP), bevacizumab plus carboplatin plus paclitaxel (BCP), or atezolizumab plus BCP (ABCP) every 3 weeks for four or six cycles, followed by maintenance therapy with atezolizumab, bevacizumab, or both. The two primary end points were investigator-assessed progression-free survival both among patients in the intention-to-treat population who had a wild-type genotype (WT population; patients with EGFR or ALK genetic alterations were excluded) and among patients in the WT population who had high expression of an effector T-cell (Teff) gene signature in the tumor (Teff-high WT population) and overall survival in the WT population. The ABCP group was compared with the BCP group before the ACP group was compared with the BCP group. Results In the WT population, 356 patients were assigned to the ABCP group, and 336 to the BCP group. The median progression-free survival was longer in the ABCP group than in the BCP group (8.3 months vs. 6.8 months; hazard ratio for disease progression or death, 0.62; 95% confidence interval [CI], 0.52 to 0.74; P

Published
2018

9. Pembrolizumab (pembro) + chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407

Author

Paz-Ares, L., primary, Vicente, D., additional, Tafreshi, A., additional, Robinson, A., additional, Soto Parra, H., additional, Mazières, J., additional, Hermes, B., additional, Cicin, I., additional, Medgyasszay, B., additional, Beatrix, B., additional, Rodríguez Cid, J., additional, Okamoto, I., additional, Lee, S., additional, Ramlau, R., additional, Vladimirov, V., additional, Cheng, Y., additional, Deng, X., additional, Bas, T., additional, Piperdi, B., additional, and Halmos, B., additional

Published
2019
Full Text
View/download PDF

11. P2.09-21 Women with Synchronous or Metachronous Lung and Ovarian Cancers: A Multi-Institutional Report

Author

Mariniello, A., primary, Ghisoni, E., additional, Righi, L., additional, Catino, A., additional, Chiari, R., additional, Del Conte, A., additional, Barbieri, F., additional, Cecere, F.L., additional, Gelibter, A., additional, Giaj Levra, M., additional, Soto Parra, H., additional, Zichi, C., additional, Valabrega, G., additional, and Novello, S., additional

Published
2018
Full Text
View/download PDF

13. P1.01-53 Bone Metastases and Efficacy of Immunotherapy in Patients with Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Author

Landi, L., primary, D'Incà, F., additional, Cortesi, E., additional, Chiari, R., additional, Grossi, F., additional, Delmonte, A., additional, De Marinis, F., additional, Signorelli, D., additional, Dazzi, C., additional, Sperandi, F., additional, Catino, A., additional, Giannarelli, D., additional, Soto Parra, H., additional, Minuti, G., additional, Bordi, P., additional, Migliorino, M.R., additional, Palla, A., additional, Tonini, G., additional, Cognetti, F., additional, Santoro, A., additional, Tassinari, D., additional, Scoppola, A., additional, Bidoli, P., additional, Piantedosi, F., additional, Maio, M., additional, Crinò, L., additional, and Cappuzzo, F., additional

Published
2018
Full Text
View/download PDF

16. Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria

Author

Stefano A, Russo G, Ippolito M, Cosentino S, Murè G, Baldari S, Mg, Sabini, Sardina D, Lucia Valastro, Bordonaro R, Messa C, Mc, Gilardi, Soto Parra H, Stefano, A., Russo, G., Ippolito, M., Cosentino, S., Murè, G., Baldari, S., Sabini, M., Sardina, D., Valastro, L., Bordonaro, R., Messa, C., Gilardi, M., Soto Parra, H., Stefano, A, Russo, G, Ippolito, M, Cosentino, S, Murè, G, Baldari, S, Sabini, M, Sardina, D, Valastro, L, Bordonaro, R, Messa, M, Gilardi, M, and Soto Parra, H

Subjects
Adult, Male, Lung Neoplasms, Time Factors, Antineoplastic Agents, Kaplan-Meier Estimate, Aged, Carcinoma, Non-Small-Cell Lung, Disease-Free Survival, Erlotinib Hydrochloride, Female, Humans, Middle Aged, Positron Emission Tomography Computed Tomography, Prospective Studies, Treatment Outcome, Response evaluation criteria in solid tumor, non–small cell lung cancer, Non-Small-Cell Lung, Carcinoma, Carcinoma, non-small-cell lung, EORTC, RECIST, Response evaluation criteria in solid tumors, Positron-emission tomography, PERCIST, Diagnosi, 18F-FDG PET
Abstract

BACKGROUND: In this paper the clinical value of PET for early prediction of tumor response to erlotinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen is evaluated. The aim was to compare the early metabolic treatment response using European Organization for Research and Treatment of Cancer (EORTC) 1999 recommendations and PET Response Criteria in Solid Tumors (PERCIST), and the standard treatment response using Response Evaluation Criteria in Solid Tumors (RECIST). METHODS: Twenty patients with stage IV NSCLCwere enrolled prospectively. PET/CT studies were performed before, then 48 hours, and 45 days after the initiation of erlotinib treatment. The lesion with the highest uptake in each patient was evaluated according to EORTC1999 recommendations, PERCIST and RECIST to assess metabolic and anatomic response. Response classifications were compared statistically using Wilcoxon signed-rank test. Disease-free survival (DFS) and overall survival (OS) were calculated by the Kaplan-Meier Test. RESULTS: At 48 hours, the Kaplan-Meier analysis showed that EORTC proved to be a significant prognostic factor for predicting DFS and OS. At 45 days, there was a significant difference in response evaluation between RECIST and metabolic classifications. RECIST and PERCIST were significant prognostic factors for predicting DFS and OS. EORTC was not able to discriminate responder from non-responder patients. CONCLUSIONS: This study shows that, according to the EORTC protocol, the PET exam is able to provide early identification of patients who benefit from Erlotinib treatment. Used at the end of therapy, PERCIST could be considered an appropriate metabolic evaluation method to discriminate responders from non-responders.

Published
2014

17. Efficacy of ceritinib administered to patients with crizotinib-refractory, ALK-positive, advanced NSCLC within the Italian compassionate use program

Author

Metro, G., primary, Passaro, A., additional, Lo Russo, G., additional, Bonanno, L., additional, Giusti, R., additional, Gregorc, V., additional, Capelletto, E., additional, Martelli, O., additional, Cecere, F.L., additional, Giannarelli, D., additional, Luciani, A., additional, Bearz, A., additional, Tuzi, A., additional, Scotti, V., additional, Tonini, G., additional, Galetta, D., additional, Carta, A., additional, Soto Parra, H., additional, Morabito, A., additional, and Chiari, R., additional

Published
2017
Full Text
View/download PDF

19. Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria

Author

Stefano A. 1, 2, Russo G. 1, Ippolito M. 3, Cosentino S. 3, Murè G. 3, Baldari S. 3, Sabini M. G. 4, Sardina D. 4, Valastro L.M. 4, Bordonaro R. 5, Messa C. 1, 6, Gilardi M.C. 1, and Soto Parra H. 7

Subjects
neoplasms
Abstract

AIM: In this paper the clinical value of PET for early prediction of tumor response to Erlotinib in patients with advanced or metastatic nonsmall cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen is evaluated. The aim was to compare the early metabolic treatment response using European Organization for Research and Treatment of Cancer (EORTC) 1999 recommendations and PET Response Criteria in Solid Tumors (PERCIST), and the standard treatment response using Response Evaluation Criteria in Solid Tumors (RECIST). METHODS: Twenty patients with stage IV NSCLC were enrolled prospectively. PET/CT studies were performed before, then 48 h, and 45 days after the initiation of Erlotinib treatment. The lesion with the highest uptake in each patient was evaluated according to EORTC 1999 recommendations, PERCIST and RECIST to assess metabolic and anatomic response. Response classifications were compared statistically using Wilcoxon signedrank test. Disease-Free Survival (DFS) and Overall Survival (OS) were calculated by the KaplanMeier test. RESULTS: At 48 h, the KaplanMeier analysis showed that EORTC proved to be a significant prognostic factor for predicting DFS and OS. At 45 days, there was a significant difference in response evaluation between RECIST and metabolic classifications. RECIST and PERCIST were significant prognostic factors for predicting DFS and OS. EORTC was not able to discriminate responder from non-responder patients. CONCLUSION: This study shows that, according to the EORTC protocol, the PET exam is able to provide early identification of patients who benefit from Erlotinib treatment. Used at the end of therapy, PERCIST could be considered an appropriate metabolic evaluation method to discriminate responders from nonresponders.

Published
2014

21. Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population

Author

Crinò, L., primary, Bidoli, P., additional, Delmonte, A., additional, Grossi, F., additional, de Marinis, F., additional, Sperandi, F., additional, Piantedosi, F., additional, Vitali, M., additional, Soto Parra, H., additional, Scagnoli, S., additional, Minuti, G., additional, Calabrò, L., additional, Tiseo, M., additional, Turci, D., additional, Quadrini, S., additional, Antonelli, P., additional, Manzo, A., additional, Prediletto, I., additional, Giannarelli, D., additional, and Galetta, D., additional

Published
2016
Full Text
View/download PDF

22. Impact on Survival of Timing and Duration of Adjuvant Chemotherapy in Radically Resected Gastric Cancer

Author

Di Bartolomeo, Maria, primary, Pietrantonio, Filippo, additional, Rulli, Eliana, additional, Poli, Davide, additional, Berenato, Rosa, additional, Caporale, Marta, additional, Bajetta, Emilio, additional, Floriani, Irene, additional, Bajetta, E., additional, Di Bartolomeo, M., additional, Catena, L., additional, Schiavo, M., additional, Pinotti, G., additional, Proserpio, I., additional, Rosati, G., additional, Bordonaro, R., additional, Cordio, S., additional, Burrafato, G., additional, Bochicchio, A.M., additional, Aieta, M., additional, Fazio, N., additional, Spada, F., additional, Amoroso, V., additional, Marini, G., additional, Soto Parra, H., additional, Novello, G., additional, Massidda, B., additional, Ionta, M.T., additional, Comandè, M., additional, Venezia, R., additional, Bertolini, A., additional, Menatti, E., additional, Zanlorenzi, L., additional, Colombo, A., additional, Iop, A., additional, Bonura, S., additional, Mazza, E., additional, Viganò, M., additional, Ardizzoia, A., additional, Dell'Oro, S., additional, Lo Re, G., additional, Santeufemia, D., additional, Buonadonna, A., additional, Luisi, D., additional, Ucci, G., additional, Di Lucca, G., additional, Bonetti, A., additional, Bergamo, F., additional, Alù, M., additional, Vastola, F., additional, Marchetti, P., additional, Corsi, D.C., additional, Massa, E., additional, Di Pinto, G., additional, Duro, M., additional, Oliani, C., additional, Franchini, M., additional, Inzoli, A., additional, Gebbia, N., additional, Repetto, L., additional, Rota, S., additional, Frontini, L., additional, Labianca, R., additional, Mosconi, S., additional, Quadri, A., additional, De Grossi, S., additional, Bidoli, P., additional, Cazzaniga, M.E., additional, Villa, F., additional, Foa, P., additional, Ferrari, D., additional, Aitini, E., additional, Rabbi, C., additional, Barni, S., additional, Petrelli, F., additional, Giordano, M., additional, Luchena, G., additional, Pirovano, M., additional, Nasisi, A., additional, Catalano, V., additional, Giordani, P., additional, Zaniboni, A., additional, Leone, F., additional, Ferrario, S., additional, Beretta, G.D., additional, Menichetti, E.T., additional, Conte, D., additional, Mari, D., additional, Giannicola, R., additional, Pierantoni, C., additional, Luporini, A.G., additional, Ragazzini, A., additional, Ravaioli, A., additional, Tassinari, D., additional, Nicolini, M., additional, Amadori, D., additional, Frassineti, G.L., additional, Turci, D., additional, Zumaglini, F., additional, Tamberi, S., additional, Piancastelli, A., additional, Cruciani, G., additional, Bejtja, E., additional, Falcone, A., additional, Landi, L., additional, Minuti, G., additional, Cantore, M., additional, Orlandi, M., additional, Mambrini, A., additional, Ciarlo, A., additional, Cavaciocchi, D., additional, Del Monte, F., additional, Ricci, S., additional, Brunetti, I.M., additional, Lencioni, M., additional, Sisani, M., additional, Sozzi, P., additional, Granetto, C., additional, Chiara, S., additional, Galetto, A.S., additional, Ribecco, A.S., additional, DeCensi, A., additional, Ciuffreda, L., additional, Baldini, E.E., additional, Camisa, R., additional, Todeschini, R., additional, Santoro, A., additional, Rimassa, L., additional, Carnaghi, C., additional, Pressiani, T., additional, Boni, C., additional, Rondini, E., additional, Gnoni, R., additional, Di Costanzo, F., additional, Gasperoni, S., additional, Cavanna, L., additional, Palladino, M.A., additional, Mattioli, R., additional, Laici, G., additional, Pucci, F., additional, Alessio, M.D., additional, Bernardini, I., additional, Tomasello, G., additional, Baldino, G., additional, Rossetti, R., additional, Giaquinta, S., additional, Pinto, C., additional, Di Fabio, F., additional, Rijas Llimpe, F.L., additional, Brandes, A.A., additional, Marzola, M., additional, Rummo Benevento, A.O.G., additional, Competiello, S., additional, Montesarchio, V., additional, Rea, A., additional, Daniele, B., additional, Genua, G., additional, Licenziato, M., additional, Casaretti, R., additional, Silvestro, L., additional, Montano, M., additional, Sarobba, M.G., additional, Sanna, G., additional, Filippelli, G., additional, Dima, G., additional, Greco, E., additional, Roselli, M., additional, Natale, D., additional, Condemi, G., additional, Fumi, G., additional, Tafuto, S., additional, Masullo, P., additional, Nitti, D., additional, Marchet, A., additional, Tiberio, G., additional, de Manzoni, G., additional, Nobili, S., additional, Fiorentini, G., additional, Mazzanti, R., additional, Perrotta, E., additional, Carlomagno, C., additional, De Stefano, A., additional, Cartenì, G., additional, and Otero, M., additional

Published
2016
Full Text
View/download PDF

23. Efficacy of Mitomycin C plus a Fluoropyrimidine in pre-treated patients with metastatic colo-rectal cancer eligible to Regorafenib. Results of a retrospective study

Author

Martines, C., primary, Cordio, S., additional, Soto-Parra, H., additional, Novello, G., additional, Burrafato, G., additional, Martorana, F., additional, Aiello, M., additional, Mattina, M., additional, Uccello, M., additional, Bordonaro, R., additional, and Vigneri, P., additional

Published
2015
Full Text
View/download PDF

27. Non-small-cell lung cancer patients unsuitable for first-line chemotherapy: A new category of patients for clinical studies?

Author

Soto Parra, H., Latteri, F., Cavina, R., De Vincenzo, F., Zucali, P. A., Campagnoli, E., and Santoro, A.

Subjects
Diarrhea, Male, Lung Neoplasms, Patient Selection, Carcinoma, Antineoplastic Agents, Gefitinib, Exanthema, Survival Analysis, Treatment Outcome, 80 and over, Quinazolines, Humans, Female, Non-Small-Cell Lung, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung
Published
2005

30. Soft tissue and bone sarcomas

Author

Santoro, Armando and Soto Parra, H

Subjects
Osteosarcoma, Ewing, Humans, Bone Neoplasms, Sarcoma, Prognosis, Sarcoma, Ewing
Published
1999

31. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease

Author

Bonfante, V., Viviani, S., Santoro, A., Devizzi, L., Di Russo, A., Zanini, M., Soncini, F., Soto Parra, H., Valagussa, P., and Bonadonna, G.

Subjects
Adult, Male, Salvage Therapy, Neutropenia, Hodgkin's disease, Ifosfamide, Recurrent disease, Salvage therapy, Vinorelbine, Antineoplastic Combined Chemotherapy Protocols, Female, Hodgkin Disease, Humans, Middle Aged, Pilot Projects, Recurrence, Treatment Outcome, Vinblastine
Abstract

Twenty-six patients with relapsed or refractory Hodgkin's disease (HD) were treated with an intensive salvage regimen combining ifosfamide (3000 mg/m2/d, days 1-4 through continuous intravenous infusion) and vinorelbine (25 mg/m2, i.v. days 1 and 5) with mesna uroprotection and G-CSF support. Courses were given at 3-week intervals. Ten patients achieved a complete and 10 patients a partial response, yielding an overall response rate of 77%. The main toxic effect was neutropenia and the combination was well tolerated.

Published
1998

32. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma

Author

Ceresoli, G L, primary, Zucali, P A, additional, Mencoboni, M, additional, Botta, M, additional, Grossi, F, additional, Cortinovis, D, additional, Zilembo, N, additional, Ripa, C, additional, Tiseo, M, additional, Favaretto, A G, additional, Soto-Parra, H, additional, De Vincenzo, F, additional, Bruzzone, A, additional, Lorenzi, E, additional, Gianoncelli, L, additional, Ercoli, B, additional, Giordano, L, additional, and Santoro, A, additional

Published
2013
Full Text
View/download PDF

33. Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy.

Author

Houédé, N., Locker, G., Lucas, C., Soto Parra, H., Basso, U., Spaeth, D., Tambaro, R., Basterretxea, L., Morelli, F., Theodore, C., Lusuardi, L., Lainez, N., Guillot, A., Tonini, G., Bielle, J., and Garcia Del Muro, X.

Subjects
TRANSITIONAL cell carcinoma, PLATINUM, CANCER chemotherapy, CANCER relapse, CISPLATIN, THERAPEUTICS
Abstract

Background: Platinum-based systemic chemotherapy is considered the backbone for management of advanced urothelial carcinomas. However there is a lack of real world data on the use of such chemotherapy regimens, on patient profiles and on management after treatment failure. Methods: Fifty-one randomly selected physicians from 4 European countries registered 218 consecutive patients in progression or relapse following a first platinum-based chemotherapy. Patient characteristics, tumor history and treatment regimens, as well as the considerations of physicians on the management of urothelial carcinoma were recorded. Results: A systemic platinum-based regimen had been administered as the initial chemotherapy in 216 patients: 15 in the neoadjuvant setting, 61 in adjuvant therapy conditions, 137 in first-line advanced setting and 3 in other conditions. Of these patients, 76 (35 %) were initially considered as cisplatin-unfit, mainly because of renal impairment (52 patients). After platinum failure, renal impairment was observed in 44 % of patients, ECOG Performance Status ≥ 2 in 17 %, hemoglobinemia < 10 g/dL in 16 %, hepatic metastases in 13 %. 80 % of these patients received further anticancer therapy. Immediately after failure of adjuvant/neoadjuvant chemotherapy, most subsequent anticancer treatments were chemotherapy doublets (35/58), whereas after therapy failure in the advanced setting most patients receiving further anticancer drugs were treated with a single agent (80/114). After first progression to chemotherapy, treatment decisions were mainly driven by Performance Status and prior response to chemotherapy (>30 % patients). The most frequent all-settings second anticancer therapy regimen was vinflunine (70 % of single-agent and 42 % of all subsequent treatments), the main reasons evoked by physicians (>1 out of 4) being survival benefit, safety and phase III evidence. Conclusion: In this daily practice experience, a majority of patients with urothelial carcinoma previously treated with a platinum-based therapy received a second chemotherapy regimen, most often a single agent after an initial chemotherapy in the advanced setting and preferably a cytotoxic combination after a neoadjuvant or adjuvant chemotherapy. Performance Status and prior response to chemotherapy were the main drivers of further treatment decisions. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

37. Usefulness of 18FDG-positron emission tomography (FDG-PET) for early prediction of erlotinib (Eb) treatment outcome in non-small cell lung cancer (NSCLC) patients: Results of a pilot study

Author

Soto Parra, H. J., primary, Ippolito, M., additional, Tiseo, M., additional, Cosentino, S., additional, Ardizzoni, A., additional, Latteri, F., additional, Pumo, V., additional, Cordio, S., additional, Bordonaro, R., additional, and Spadaro, P., additional

Published
2009
Full Text
View/download PDF

48. Four cycles of ABVD followed by involved field irradiation (IF-RT) is the treatment of choice for early-stage Hodgkin's disease (HD): 5-year results of a randomized trial

Author

Santoro, A., primary, Bonfante, V., additional, Viviani, S., additional, Zanini, M., additional, Devizzi, L., additional, Soto Parra, H., additional, Di Russo, A., additional, Soncini, F., additional, Villani, F., additional, Valagussa, P., additional, and Bonadonna, G, additional

Published
1997
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results